Selectis Health, Inc 8-K, filed Feb 22, 2024
Selectis Health, Inc. (GBCS)
About this 8-K
Selectis Health, Inc filed this 8-K on February 22, 2024, reporting on events of February 20, 2024.
Items reported
- Item 1.02: Ended a material agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation) |
Commission File Number |
(I.R.S. Employer Identification number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
| Written communications pursuant to Rule 425 under the Securities Act | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT
Effective February 20, 2024, Selectis Health, Inc., a Utah corporation (the “Company”) received written notice from the Purchaser (“Purchaser”) under the Purchase and Sale Agreement (“PSA”) and Operations Transfer Agreement (“OTA”) for the sale of certain of its Georgia subsidiaries, as previously reported on its Current Report on Form 8-K dated November 30, 2023 and filed with the Securities and Exchange Commission on December 5, 2023, that the Purchaser was terminating the PSA and OTA without consummation.
In the notice the Purchaser claimed several Events of Default by the Company under the PSA and OTA. The Company categorically denies that those claimed Events of Default occurred.
The Company intends to pursue any and all rights and remedies in the matter.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Selectis Health, Inc. | |
| (Registrant) | |
| Dated: February 22, 2024 | /s/ Adam Desmond |
| Adam Desmond, Interim CEO |